Citations

Showing 10 of 108094 citations.

Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer
Matsuo, Koji , Mariani, Andrea , Mandelbaum, Rachel S. , Gostout, Bobbie S., Roman, Lynda D. , Machida, Hiroko , Glaser, Gretchen E., Roman, Lynda D , Glaser, Gretchen , Wright, Jason Dennis

Mayo Clinic

Journal of Gynecologic Oncology | May 9, 2018 | Volume: 29 | Issue: 5 | Pages: No page available

10.3802/jgo.2018.29.e69 | PMID 30022633 Get It

Vasomotor symptoms in women over 60: results from the Data Registry on Experiences of Aging, Menopause, and Sexuality (DREAMS)
David, Paru S., Kling, Juliana M. , Vegunta, Suneela , Kapoor, Ekta , Mara, Kristin C. , Schroeder, Darrell R. , Hilsaca, Karla Frohmader, Kuhle, Carol L. , Mara, Kristin C , Kling, Juliana M , Schroeder, Darrell , Faubion, Stephanie S. , Hilsaca, Karla S. Frohmader

Mayo Clinic

Menopause | May 9, 2018 | Volume: 25 | Issue: 10 | Pages: 1105-1109

10.1097/gme.0000000000001126 | PMID 29738420 Get It

Abstract Objective: Frequency of vasomotor symptoms (VMS) in older women and the contributing factors are largely undefined. We measured the frequency of moderate-to-severe vasomotor symptoms (msVMS) in women ≥60 years of age and examined their characteristics to determine factors that may associate with VMS in older women. Methods: A cross-sectional survey was completed using the Menopause Health Questionnaire from the Data Registry on Experiences of Aging, Menopause, and Sexuality. Data were collected from women presenting for menopause consultation to Mayo Clinic, Rochester, MN, from January 1, 2006 to October 7, 2014. We created a binary variable where women were classified as having msVMS bother if they reported “quite a bit” or “extremely” compared with women reporting “not at all” or “a little bit.” Women with and without msVMS were evaluated by menopause type, self-rated heath, current tobacco, caffeine, and alcohol use, as well as pertinent medication use. Associations between participant characteristics and msVMS were evaluated using logistic regression and a multivariable model with age as a covariate. Interactions between participant characteristics and age were also assessed. Results: Of the 4,956 women presenting for menopause consultation, 921 (18%) were ≥60 years old. Of these, 379 (41.2%) reported msVMS bother. Women with msVMS were more likely to have a history of nonspontaneous menopause and report their health as fair, versus good or excellent. Women reporting current use of hormone therapy (HT) (21%) were less likely to report msVMS compared with those not taking HT (P < 0.001). Conclusions: A substantial number of women seen in a specialty menopause clinic were over age 60 years and reported msVMS, highlighting that VMS may be disruptive in women over a decade past the natural age of menopause.
SLCO1B1 genetic variation and hormone therapy in menopausal women
Moyer, Ann M. , Kapoor, Ekta , Dudenkov, Tanda M., Weinshilboum, Richard M. , Miller, Virginia M. , de Andrade, Mariza, Dudenkov, Tanda, Andrade, Mariza de , Faubion, Stephanie S. , Weinshilboum, Richard M.

Mayo Clinic

Menopause | May 9, 2018 | Volume: 25 | Issue: 8 | Pages: 877-882

10.1097/gme.0000000000001109 | PMID 29738412 Get It

Abstract Objective: Response to menopausal hormone therapy (MHT) shows individual variation. SLCO1B1 encodes the OATP1B1 transporter expressed in the liver that transports many endogenous substances, including estrone sulfate, from the blood into hepatocytes. This study evaluated the relationship between genetic variation in SLCO1B1 and response to MHT in women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS) at Mayo Clinic, Rochester, MN. Methods: KEEPS participants were randomized to oral conjugated equine estrogen (n = 33, oCEE), transdermal 17β-estradiol (n = 33, tE2), or placebo (n = 34) for 48 months. Menopausal symptoms (hot flashes, night sweats, insomnia, palpitations) were self-reported before treatment and at 48 months. Estrone (E1), E2, and sulfated conjugates (E1S, E2S) were measured using high-performance liquid chromatography-tandem mass spectrometry. SLCO1B1 rs4149056 (c.521T>C, p.Val174Ala) was genotyped using a TaqMan assay. Results: After adjusting for treatment, there was a significant association between the SLCO1B1 rs4149056 TT genotype (encoding normal function transporter) and lower E1S, E1S/E1, and E2S (P = 0.032, 0.010, and 0.008, respectively) compared with women who were heterozygous (TC) or homozygous (CC) for the reduced function allele. The interactions between genotype, treatment, and E2S concentration were stronger in women assigned to tE2 (P = 0.013) than the women taking oCEE (P = 0.056). Among women assigned to active treatment, women with the CT genotype showed a significantly greater decrease in night sweats (P = 0.041) than those with the TT genotype. Conclusions: Individual variation in sulfated estrogens is explained, in part, by genetic variation in SLCO1B1. Bioavailability of sulfated estrogens may contribute to relief of night sweats.
Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants
Kumar, Anita J. , Hemmer, Michael, Arora, Mukta , Pidala, Joseph A. , Couriel, Daniel R. , Aljurf, Mahmoud , Cahn, Jean‐Yves, Cairo, Mitchell S. , Farhan, Shatha , Hale, Gregory A., Hashmi, Shahrukh K. , Inamoto, Yoshihiro , Kamble, Rammurti T., Kharfan‐Dabaja, Mohamed A. , MacMillan, Margaret L. , Marks, David I. , Norkin, Maxim , Ringdén, Olle , Schouten, Harry C. , Solh, Melhem , Urbano-Ispizúa, Álvaro , Verdonck, Leo F. , Hamilton, Betty K. , Majhail, Navneet S. , Loren, Alison W. , Ringden, Olov , Majhail, Navneet S , Kim, Soyoung , Spellman, Stephen R. , Alousi, Amin Majid , Cahn, Jean‐Yves , Cutler, Corey S. , Gergis, Usama , Nakasone, Hideki , Qayed, Muna , Schultz, Kirk R. , Teshima, Takanori , Gale, Robert Peter

Mayo Clinic

Blood Advances | May 8, 2018 | Volume: 2 | Issue: 9 | Pages: 1022-1031

10.1182/bloodadvances.2017013052 | PMID 29739773 Get It

Key Points Compared with parous female sibling donors, male URDs confer more aGVHD in all patients and more cGVHD in females. There was no difference in survival, relapse, or transplant mortality between recipients of parous female sibling or male URD grafts.
A Contribution to Treatment of Superego Defect
Johnson, Adelaide M.

Mayo Clinic

Social Casework | May 8, 2018 | Volume: 31 | Issue: 4 | Pages: 135-138

10.1177/104438945003100401 Get It

Heat Stress and Hepatic Laser Thermal Ablation Induce Hepatocellular Carcinoma Growth: Role of PI3K/mTOR/AKT Signaling
Jondal, Danielle E. , Thompson, Scott M. , Butters, Kim A., Anderson, J. L. , Carter, Rickey E. , Roberts, Lewis R. , Callstrom, Matthew R. , Woodrum, David A. , Knudsen, Bruce E. , Anderson, Jill L, Roberts, Lewis R , Carter, Rickey E , Anderson, Jill L., Thompson, Scott

Mayo Clinic

Radiology | May 8, 2018 | Volume: 288 | Issue: 3 | Pages: 730-738

10.1148/radiol.2018172944 | PMID 29737948 Get It

Accumulation of Gadolinium in Human Cerebrospinal Fluid after Gadobutrol-enhanced MR Imaging: A Prospective Observational Cohort Study
Nehra, Avinash , McDonald, Robert J. , Bluhm, Amy M., Gunderson, Tina M. , Murray, David , Jannetto, Paul J. , Kallmes, David F. , Eckel, Laurence J. , McDonald, Jennifer S. , Nehra, Avinash K, Murray, David L.

Mayo Clinic

Radiology | May 8, 2018 | Volume: 288 | Issue: 2 | Pages: 416-423

10.1148/radiol.2018171105 | PMID 29737947 Get It

Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry
Wang, Tracy Y., Mi, Xiaojuan, Louie, Michael J. , Lee, L. Veronica, Goldberg, Anne C. , Roger, Véronique L. , Robinson, Jennifer G. , Nanna, Michael G. , Návar, Ann Marie , Virani, Salim S. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | May 8, 2018 | Volume: 7 | Issue: 10 | Pages: No page available

10.1161/jaha.118.008546 | PMID 29739801 Get It

Background Current statin use and symptoms among older adults in routine community practice have not been well characterized since the release of the 2013 American College of Cardiology/American Heart Association guideline. Methods and Results We compared statin use and dosing between adults >75 and ≤75 years old who were eligible for primary or secondary prevention statin use without considering guideline‐recommended age criteria. The patients were treated at 138 US practices in the Patient and Provider Assessment of Lipid Management (PALM) registry in 2015. Patient surveys also evaluated reported symptoms while taking statins. Multivariable logistic regression models examined the association between older age and statin use and dosing. Among 6717 people enrolled, 1704 (25%) were >75 years old. For primary prevention, use of any statin or high‐dose statin did not vary by age group: any statin, 62.6% in those >75 years old versus 63.1% in those ≤75 years old ( P =0.83); high‐dose statin, 10.2% versus 12.3% in the same groups ( P =0.14). For secondary prevention, older patients were slightly less likely to receive any statin (80.1% versus 84.2% [ P =0.003]; adjusted odds ratio, 0.81; 95% confidence interval, 0.66–1.01 [ P =0.06]), but were much less likely to receive a high‐intensity statin (23.5% versus 36.2% [ P <0.0001]; adjusted odds ratio, 0.54; 95% confidence interval, 0.45–0.65 [ P =0.0001]). Among current statin users, older patients were slightly less likely to report any symptoms (41.3% versus 46.6%; P =0.003) or myalgias (27.3% versus 33.3%; P <0.001). Conclusions Overall use of statins was similar for primary prevention in those aged >75 years versus younger patients, yet older patients were less likely to receive high‐intensity statins for secondary prevention. Statins appear to be similarly tolerated in older and younger adults.
Association Between Adiposity and Lean Mass With Long‐Term Cardiovascular Events in Patients With Coronary Artery Disease: No Paradox
Medina‐Inojosa, José R. , Jean, Nathalie, Jenkins, Sarah M. , Gomez‐Ibarra, Miguel Angel, Supervía, Marta , Gomez-Ibarra, Miguel Angel, Medina-Inojosa, José R , Somers, Virend K. , Thomas, Randal J. , López-Jiménez, Francisco

Mayo Clinic

Journal of the American Heart Association | May 8, 2018 | Volume: 7 | Issue: 10 | Pages: No page available

10.1161/jaha.117.007505 | PMID 29739793 Get It

Background Prognosis based on body fat percentage ( BF %) in patients with coronary artery disease has not been extensively studied. We tested the hypothesis that patients with coronary artery disease and increased BF % have a higher risk for major adverse cardiovascular events ( MACEs ) and that fat‐free mass is associated with better prognosis. Methods and Results We included 717 patients referred to cardiac rehabilitation after coronary artery disease events or procedures who underwent air displacement plethysmography to assess BF %; 75% were men, with a mean age 61.4±11.4 years and a mean body mass index of 30±5.4 kg/m 2 . Follow‐up was performed using a record linkage system. Patients were classified in sex‐specific quartiles of BF % and fat‐free mass index. The composite outcome of MACEs included acute coronary syndromes, coronary revascularization, stroke, or death from any cause. After a median follow‐up of 3.9 years, 201 patients had a MACE . After adjusting for covariates, body mass index was not associated with MACEs ( P =0.12). However, the risk of MACEs for those in the highest BF % quartile was nearly double when compared with those in the lowest quartile (hazard ratio, 1.89; 95% confidence interval, 1.30–2.77; P =0.0008). In contrast, fat‐free mass was inversely associated with MACEs . The risk of MACEs for those in the fourth fat‐free mass quartile was lower (adjusted hazard ratio, 0.53; 95% confidence interval, 0.35–0.82; P =0.004), when compared with those in the first quartile. Conclusions In patients with coronary artery disease, there is no obesity paradox when measuring BF % instead of body mass index. BF % is associated with a higher risk of MACEs , whereas fat‐free mass is associated with a lower risk of MACEs . Body mass index was not associated with MACEs .
Copeptin to rule out myocardial infarction in Blacks versus Caucasians
Beri, Neil , Daniels, Lori B. , Jaffe, Allan S. , Mueller, Christian, Schreiber, Donald , McCord, James , Limkakeng, Alexander T. , Wu, Alan H.B. , Apple, Fred S. , Diercks, Deborah B. , Nagurney, John T., Nowak, Richard M. , Cannon, Chad , Clopton, Paul , Neath, Sean‐Xavier , Christenson, Robert H. , Vilke, Gary M. , Maisel, Alan S. , Jaffe, Allan, Daniels, Lori B , Jaffe, Allan S. , Anand, Inder S. , Peacock, William Frank , Hollander, Judd E. , deFilippi, Christopher R. , Hogan, Christopher J.

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | May 8, 2018 | Volume: 8 | Issue: 5 | Pages: 395-403

10.1177/2048872618772500 | PMID 29737180 Get It

Background: Copeptin in combination with troponin has been shown to have incremental value for the early rule-out of myocardial infarction, but its performance in Black patients specifically has never been examined. In light of a potential for wider use, data on copeptin in different relevant cohorts are needed. This is the first study to determine whether copeptin is equally effective at ruling out myocardial infarction in Black and Caucasian races. Methods: This analysis of the CHOPIN trial included 792 Black and 1075 Caucasian patients who presented to the emergency department with chest pain and had troponin-I and copeptin levels drawn. Results: One hundred and forty-nine patients were diagnosed with myocardial infarction (54 Black and 95 Caucasian). The negative predictive value of copeptin at a cut-off of 14 pmol/l (as in the CHOPIN study) for myocardial infarction was higher in Blacks (98.0%, 95% confidence interval (CI) 96.2–99.1%) than Caucasians (94.1%, 95% CI 92.1–95.7%). The sensitivity at 14 pmol/l was higher in Blacks (83.3%, 95% CI 70.7–92.1%) than Caucasians (53.7%, 95% CI 43.2–64.0%). After controlling for age, hypertension, heart failure, chronic kidney disease and body mass index in a logistic regression model, the interaction term had a P value of 0.03. A cut-off of 6 pmol/l showed similar sensitivity in Caucasians as 14 pmol/l in Blacks. Conclusions: This is the first study to identify a difference in the performance of copeptin to rule out myocardial infarction between Blacks and Caucasians, with increased negative predictive value and sensitivity in the Black population at a cut-off of 14 pmol/l. This also holds true for non-ST-segment elevation myocardial infarction and, although numbers were small, similar trends exist in the normal troponin population. This may have significant implications for early rule-out strategies using copeptin.